Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

8 results

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated as a complete regimen for treating HIV-1 infection in adults and adolescents (12 years and older, weighing at least 35 kg) who are virologically suppressed on a stable antiretroviral regimen, with no history of treatment failure or resistance to cabotegravir or rilpivirine.

  • complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.

  • delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

  • edurant

    (rilpivirine hydrochloride)
    Janssen Products, LP
    EDURANT is indicated for the treatment of HIV-1 in treatment-naïve patients aged 2 and older with specific viral loads. It is also used in combination with cabotegravir for short-term treatment in adults and adolescents who are virologically suppressed and require an oral lead-in or temporary oral therapy.

  • intelence

    (etravirine)
    Janssen Products LP
    INTELENCE is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults and pediatric patients aged 2 years and older.

  • juluca

    (dolutegravir sodium and rilpivirine hydrochloride)
    ViiV Healthcare Company
    JULUCA is indicated for treating HIV-1 infection in virologically suppressed adults, replacing their current antiretroviral regimen. Eligible patients must have maintained suppression for at least 6 months, have no treatment failures, and no known resistance to JULUCA's components.

  • odefsey

    (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    ODEFSEY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) as initial therapy for those with no prior treatment and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically-suppressed patients with specific criteria.

  • pifeltro

    (doravirine)
    Merck Sharp & Dohme LLC
    PIFELTRO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents, either for those with no prior treatment history or to replace a stable regimen in virologically-suppressed patients without treatment failure history.